# LYell SYndrome MEsenchymal Stromal Cells Treatment

> **NCT04711200** · PHASE1,PHASE2 · RECRUITING · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 15 (estimated)

## Conditions studied

- Epidermal Necrolysis
- Lyell Syndrome
- Toxic Epidermal Necrolysis
- Overlap Syndrome
- Mesenchymal Stromal Cells
- Adipose Derived Stromal Cells

## Interventions

- **DRUG:** Adipose derived stromal cells intravenously injected

## Key facts

- **NCT ID:** NCT04711200
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-15
- **Primary completion:** 2027-04
- **Final completion:** 2027-04
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2025-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04711200

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04711200, "LYell SYndrome MEsenchymal Stromal Cells Treatment". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04711200. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*